NorthWest Biotherapeutics Inc (NWBO)

[MI Dendream]

I believe the 28% that you are referring to is the 2018 3 year conditional survival data point as estimated by KM to be 28.2%.. if I recall correctly, the median survival aka 14.1% was 88.2 months or 7+ years. These are early patients however and we see that this is likely to improve as more patients work their way through time. I estimate 17-20%. Once you break these out by early vs delayed treatment, you will quite likely find your 28% to be smack dab in the ballpark which is then between 1/4 and 1/3 reaching 7-8 years, but possibly short of 1/4.

All speculation including whether Keymours was unblinded and whether the slip was intended or Freudian or just guessing.

Some would call my TLD comment speculation others would not, i.e., primary endpoint has been met.